obesity drug news today glp-1 october 2025 Weight-Loss Demonstration Begins July 2026 GLP-1s for Weight Loss: What

16 (12) e76007

CNN recently reported growing scientific and regulatory attention surrounding ibogaine research, particularly in areas involving opioid addiction and treatment-resistant mental health conditions

Bendahan D, Mattei JP, Ghattas B, Confort-Gouny S, Le Guern ME, Cozzone PJ

Based on this evidence, it is recommended that long-term pharmacological management prioritize the optimization of treatment timing, formulation of personalized dosing regimens, and implementation of systematic efficacy monitoring and adverse reaction assessment protocols, to maximize therapeutic benefits while minimizing potential risks